Axel Hoos

Summary

Affiliation: Bristol-Myers Squibb
Country: USA

Publications

  1. doi request reprint Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
  2. pmc Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
    Dennis A Revicki
    United BioSource Corporation, Bethesda, MD 20814, USA
    Health Qual Life Outcomes 10:66. 2012
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
  4. pmc A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols
    Sebastian Attig
    Division of Translational and Experimental Oncology, Department of Internal Medicine III, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
    J Transl Med 9:108. 2011
  5. pmc Improved endpoints for cancer immunotherapy trials
    Axel Hoos
    Cancer Immunotherapy Consortium of the Cancer Research Institute, New York, NY, USA
    J Natl Cancer Inst 102:1388-97. 2010
  6. doi request reprint Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy
    Axel Hoos
    Global Clinical Research, Oncology, Bristol Myers Squibb Co, Wallingford, CT 06492, USA
    Semin Oncol 37:533-46. 2010
  7. ncbi request reprint A clinical development paradigm for cancer vaccines and related biologics
    Axel Hoos
    Bristol Myers Squibb, Global Clinical Research, Oncology, Wallingford, CT 06492, USA
    J Immunother 30:1-15. 2007
  8. ncbi request reprint Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis
    Axel Hoos
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3841-9. 2002
  9. ncbi request reprint Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone
    Aviram Nissan
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4078-84. 2006
  10. ncbi request reprint Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 34:54-64. 2003

Collaborators

Detail Information

Publications22

  1. doi request reprint Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy and Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 15:7412-20. 2009
    ..Novel criteria for the evaluation of antitumor responses with immunotherapeutic agents are required...
  2. pmc Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
    Dennis A Revicki
    United BioSource Corporation, Bethesda, MD 20814, USA
    Health Qual Life Outcomes 10:66. 2012
    ..This report summarizes health-related quality of life (HRQL) outcomes for ipilimumab with/without gp100 vaccine compared to gp100 alone during the clinical trial's 12 week treatment induction period...
  3. pmc Defining the critical hurdles in cancer immunotherapy
    Bernard A Fox
    Earle A, Chiles Research Institute, Robert W, Franz Research Center, Providence Cancer Center, Providence Portland Medical Center, Portland, OR, USA
    J Transl Med 9:214. 2011
    ..Each of these hurdles can significantly delay clinical translation of promising advances in immunotherapy yet if overcome, have the potential to improve outcomes of patients with cancer...
  4. pmc A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols
    Sebastian Attig
    Division of Translational and Experimental Oncology, Department of Internal Medicine III, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
    J Transl Med 9:108. 2011
    ..However, the impact of the introduction of a DUMP channel in multimer assays has so far not been systematically investigated across a broad variety of protocols...
  5. pmc Improved endpoints for cancer immunotherapy trials
    Axel Hoos
    Cancer Immunotherapy Consortium of the Cancer Research Institute, New York, NY, USA
    J Natl Cancer Inst 102:1388-97. 2010
    ..These recommendations may improve our tools for cancer immunotherapy trials and may offer a more realistic and useful model for clinical investigation...
  6. doi request reprint Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy
    Axel Hoos
    Global Clinical Research, Oncology, Bristol Myers Squibb Co, Wallingford, CT 06492, USA
    Semin Oncol 37:533-46. 2010
    ..Overall, lessons from the development of ipilimumab contributed to a new clinical paradigm for cancer immunotherapy evolved by the Cancer Immunotherapy Consortium...
  7. ncbi request reprint A clinical development paradigm for cancer vaccines and related biologics
    Axel Hoos
    Bristol Myers Squibb, Global Clinical Research, Oncology, Wallingford, CT 06492, USA
    J Immunother 30:1-15. 2007
    ..In addition, this report addresses clinical development challenges and issues for combination therapies...
  8. ncbi request reprint Tissue microarray molecular profiling of early, node-negative adenocarcinoma of the rectum: a comprehensive analysis
    Axel Hoos
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Clin Cancer Res 8:3841-9. 2002
    ..This study evaluates such molecular phenotypes with regard to cell cycle regulation and proliferation and determines their significance for patient outcome...
  9. ncbi request reprint Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone
    Aviram Nissan
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:4078-84. 2006
    ..The aim of this study was to identify predictors of recurrence in this group of patients to enhance treatment selection...
  10. ncbi request reprint Parathyroid neoplasms: clinical, histopathological, and tissue microarray-based molecular analysis
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Hum Pathol 34:54-64. 2003
    ..The molecular phenotype, p27(+)Bcl-2(+)Ki-67(-)mdm2(+), appears to be unique to nonmalignant parathyroid tumors, and multimarker phenotypes are more complex in carcinomas...
  11. ncbi request reprint Squamous cell carcinoma-related oncogene is highly expressed in developing, normal, and adenomatous adrenal tissue but not in aggressive adrenocortical carcinomas
    Inderpal S Sarkaria
    Laboratory of Epithelial Cancer Biology, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Surgery 136:1122-8. 2004
    ....
  12. ncbi request reprint An evidence-based approach to the surgical management of resectable pancreatic adenocarcinoma
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Am Coll Surg 196:954-64. 2003
    ..We conducted a comprehensive review of prospective randomized clinical trials and summarized the contemporary treatment of resectable pancreatic carcinoma...
  13. ncbi request reprint Hürthle cell carcinoma: a 60-year experience
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg Oncol 9:197-203. 2002
    ..The aim of this study was to define the clinical behavior and prognostic indicators of outcome in Hürthle cell cancer (HCC)...
  14. doi request reprint Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
    Jedd D Wolchok
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann N Y Acad Sci 1291:1-13. 2013
    ..Evaluation of ipilimumab is ongoing in the adjuvant setting for melanoma, and for advanced disease in nonsmall cell lung, small cell lung, prostate, ovarian, and gastric cancers. ..
  15. doi request reprint Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
    Jedd D Wolchok
    Ludwig Center for Cancer Immunotherapy, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Lancet Oncol 11:155-64. 2010
    ..Ipilimumab is a human monoclonal antibody that blocks cytotoxic T-lymphocyte antigen 4 and has shown promising activity in advanced melanoma. We aimed to ascertain the antitumour efficacy of ipilimumab in patients with advanced melanoma...
  16. pmc Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 235:424-34. 2002
    ..To define the significance of positive microscopic resection margins in a large cohort treated for soft tissue sarcoma...
  17. ncbi request reprint Randomized clinical trials in pancreatic cancer
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Surg Oncol Clin N Am 11:207-29, x. 2002
    ....
  18. ncbi request reprint Increased endocrine cells in treated rectal adenocarcinomas: a possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy
    Jinru Shia
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Surg Pathol 26:863-72. 2002
    ..The possible mechanism for the increased endocrine cells in treated rectal adenocarcinomas may be related to induction of endocrine differentiation in tumor cells by cytotoxic insult...
  19. ncbi request reprint Adrenocortical carcinoma: clinical, morphologic, and molecular characterization
    Alexander Stojadinovic
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 20:941-50. 2002
    ..To define multimolecular phenotypes of adrenocortical carcinoma (ACC) and to correlate outcome with morphologic and molecular parameters...
  20. ncbi request reprint Xenogeneic DNA immunization in melanoma models for minimal residual disease
    William G Hawkins
    Swim Across America Laboratory, Departments of Surgery and Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    J Surg Res 102:137-43. 2002
    ....
  21. ncbi request reprint p63 expression profiles in human normal and tumor tissues
    Charles J Di Como
    Division of Molecular Pathology, Department of Pathology, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Cancer Res 8:494-501. 2002
    ..The p63 gene, located on chromosome 3q27-28, is a member of the p53 gene family. The product encoded by the p63 gene has been reported to be essential for normal development...
  22. pmc Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays
    Axel Hoos
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Am J Pathol 160:175-83. 2002
    ..Molecular alterations in the p53 pathway play a role in Hürthle cell tumorigenesis, but other unidentified molecular changes seem to be required to induce the malignant phenotype...